Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Polaris, 18 Claremont Crescent, Sheffield, S10 2TA, UK.
GSK, Collegeville, Collegeville, P.A., USA.
MAGMA. 2024 Aug;37(4):697-708. doi: 10.1007/s10334-024-01192-5. Epub 2024 Aug 6.
Previous studies have revealed a substantial between-centre variability in DCE-MRI biomarkers of hepatocellular function in rats. This study aims to identify the main sources of variability by comparing data measured at different centres and field strengths, at different days in the same subjects, and over the course of several months in the same centre.
13 substudies were conducted across three facilities on two 4.7 T and two 7 T scanners using a 3D spoiled gradient echo acquisition. All substudies included 3-6 male Wistar-Han rats each, either scanned once with vehicle (n = 76) or twice with either vehicle (n = 19) or 10 mg/kg of rifampicin (n = 13) at follow-up. Absolute values, between-centre reproducibility, within-subject repeatability, detection limits, and effect sizes were derived for hepatocellular uptake rate (K) and biliary excretion rate (k). Sources of variability were identified using analysis of variance and stratification by centre, field strength, and time period.
Data showed significant differences between substudies of 31% for K (p = 0.013) and 43% for k (p < 0.001). Within-subject differences were substantially smaller for k (8%) but less so for K (25%). Rifampicin-induced inhibition was safely above the detection limits, with an effect size of 75 ± 3% in K and 67 ± 8% in k. Most of the variability in individual data was accounted for by between-subject (K = 23.5%; k = 42.5%) and between-centre (K = 44.9%; k = 50.9%) variability, substantially more than the between-day variation (K = 0.1%; k = 5.6%). Significant differences in k were found between field strengths at the same centre, between centres at the same field strength, and between repeat experiments over 2 months apart in the same centre.
Between-centre bias caused by factors such as hardware differences, subject preparations, and operator dependence is the main source of variability in DCE-MRI of liver function in rats, closely followed by biological between-subject differences. Future method development should focus on reducing these sources of error to minimise the sample sizes needed to detect more subtle levels of inhibition.
先前的研究表明,在大鼠肝细胞功能的 DCE-MRI 生物标志物方面,不同中心之间存在很大的变异性。本研究旨在通过比较不同中心和场强、同一受试者不同日期以及同一中心数月内的数据,确定变异性的主要来源。
在三个设施中进行了 13 项子研究,使用 3D 扰相梯度回波采集在两台 4.7T 和两台 7T 扫描仪上进行。所有子研究均包括 3-6 只雄性 Wistar-Han 大鼠,每组 76 只大鼠用载体单次扫描,每组 19 只大鼠用载体或 10mg/kg 利福平两次扫描,每组 13 只大鼠在随访时用利福平扫描。为肝细胞摄取率 (K) 和胆汁排泄率 (k) 得出了绝对值、中心间再现性、个体内重复性、检测限和效应大小。使用方差分析和按中心、场强和时间段分层的方法确定变异性的来源。
数据显示,K 为 31%(p=0.013),k 为 43%(p<0.001),子研究之间存在显著差异。k 的个体内差异要小得多(8%),而 K 的个体内差异要大得多(25%)。利福平诱导的抑制作用安全超过检测限,K 为 75±3%,k 为 67±8%。个体数据的大部分变异性归因于个体间(K=23.5%;k=42.5%)和中心间(K=44.9%;k=50.9%)的变异性,大大超过了日变异性(K=0.1%;k=5.6%)。在同一中心的场强之间、同一场强的中心之间以及同一中心相隔 2 个月的重复实验之间发现 k 存在显著差异。
由硬件差异、受试者准备和操作人员依赖性等因素引起的中心间偏差是大鼠肝脏 DCE-MRI 功能变异性的主要来源,紧随其后的是个体间的生物学差异。未来的方法开发应侧重于减少这些误差源,以最大限度地减少检测更细微抑制水平所需的样本量。